DiaSorin S.p.A. (VIE:DIAS)
Austria · Delayed Price · Currency is EUR | Market Cap | 3.66B -17.5% |
| Revenue (ttm) | 1.18B -3.1% |
| Net Income | 140.57M -26.6% |
| EPS | 2.69 -22.1% |
| Shares Out | n/a |
| PE Ratio | 26.07 |
| Forward PE | 16.88 |
| Dividend | 1.30 (1.70%) |
| Ex-Dividend Date | May 18, 2026 |
| Volume | n/a |
| Open | 74.94 |
| Previous Close | 75.82 |
| Day's Range | 73.92 - 74.94 |
| 52-Week Range | 54.24 - 82.96 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About DiaSorin
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine... [Read more]
Financial Performance
In 2025, DiaSorin's revenue was 1.20 billion, an increase of 0.81% compared to the previous year's 1.19 billion. Earnings were 155.62 million, a decrease of -17.27%.
Financial StatementsNews
DiaSorin downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded DiaSorin (DSRLF) to Hold from Buy with a EUR 76 price target
DiaSorin downgraded to Sell from Neutral at UBS
UBS analyst Kavya Deshpande downgraded DiaSorin (DSRLF) to Sell from Neutral with a price target of EUR 55, down from EUR 66. The firm is more cautious than the company’s…
DiaSorin price target raised to EUR 60 from EUR 58 at Deutsche Bank
Deutsche Bank raised the firm’s price target on DiaSorin (DSRLF) to EUR 60 from EUR 58 and keeps a Sell rating on the shares.
DiaSorin Earnings Call Transcript: Q2 2026
Q2 2026 saw a 4% revenue increase at constant exchange rates, driven by strong U.S. and European performance, while China and the Middle East remained challenging. Full-year guidance for 5%-6% revenue growth and 32%-33% EBITDA margin is confirmed, with robust momentum in Immunodiagnostics, LTG, and new product launches.
DiaSorin Earnings release: Q2 2026
DiaSorin released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
DiaSorin Slides: Q2 2026
DiaSorin has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 31, 2026.
DiaSorin Quarterly report: Q2 2026
DiaSorin has published its Q2 2026 quarterly earnings report on July 31, 2026.
DiaSorin downgraded to Underperform from Neutral at BNP Paribas
BNP Paribas downgraded DiaSorin (DSRLF) to Underperform from Neutral with a price target of EUR 60, down from EUR 65.
DiaSorin initiated with a Buy at Kepler Cheuvreux
Kepler Cheuvreux initiated coverage of DiaSorin (DSRLF) with a Buy rating and EUR 76 price target
DiaSorin downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Jan Koch downgraded DiaSorin (DSRLF) to Sell from Hold with a price target of EUR 58, down from EUR 62. The firm believes consensus estimates underestimate the…
DiaSorin initiated with a Neutral at Piper Sandler
Piper Sandler analyst David Westenberg initiated coverage of DiaSorin (DSRLF) with a Neutral rating and EUR 75 price target The firm launched coverage of the life science tools sector with…
DiaSorin Transcript: Investor Day 2026
The five-year plan targets 6–8% CAGR through 2030, driven by specialty leadership in immuno- and molecular diagnostics, U.S. market expansion, and innovation in automation and precision medicine. Margin expansion and €1B free cash flow are expected, with disciplined capital allocation and strong ESG commitments.
DiaSorin Press release: FY 2026
DiaSorin issued a press release on May 20, 2026, disclosing material business information to investors.
DiaSorin Slides: FY 2026
DiaSorin has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 20, 2026.
DiaSorin Earnings Call Transcript: Q1 2026
Q1 2026 saw a 3% revenue decline at constant FX, mainly from weak flu season, China headwinds, and U.S. destocking, but immuno grew 1% and guidance for 5%-6% annual growth is maintained. Share buybacks and tariff changes impacted net debt and margins.
DiaSorin Earnings release: Q1 2026
DiaSorin released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
DiaSorin Slides: Q1 2026
DiaSorin has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
DiaSorin price target lowered to EUR 62 from EUR 65 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on DiaSorin (DSRLF) to EUR 62 from EUR 65 and keeps a Hold rating on the shares.
DiaSorin downgraded to Neutral from Buy at UBS
UBS analyst Kavya Deshpande downgraded DiaSorin (DSRLF) to Neutral from Buy with a price target of EUR 66, down from EUR 84. The firm sees modest risk to estimates and…
DiaSorin price target lowered to EUR 65 from EUR 74 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on DiaSorin (DSRLF) to EUR 65 from EUR 74 and keeps a Hold rating on the shares. Published first on…
DiaSorin price target lowered to EUR 60 from EUR 65 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on DiaSorin (DSRLF) to EUR 60 from EUR 65 and keeps an Equal Weight rating on the shares.
DiaSorin Earnings Call Transcript: Q4 2025
2025 saw modest revenue growth, strong immuno performance in North America, and strategic shifts in China amid VBP pressures. 2026 guidance anticipates 5%-6% revenue growth, with profitability impacted by product launches, FX, and ongoing macroeconomic headwinds.
DiaSorin Earnings release: Q4 2025
DiaSorin released its Q4 2025 earnings on March 20, 2026, summarizing the period's financial results.
DiaSorin Slides: Q4 2025
DiaSorin has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 20, 2026.
DiaSorin Annual report: Q4 2025
DiaSorin has published its Q4 2025 annual report on March 20, 2026.